Table 1.
Demographics and comorbidities of patients in the study
| Total | Any virus detected | No virus detected | A/H1 | A/H3 | INF-B | RSV | hMPV | PIV | |
|---|---|---|---|---|---|---|---|---|---|
| Cases | 1753 | 563 (32.1%) | 1190 (67.9%) | 65 (3.7%) | 177 (10.1%) | 77 (4.4%) | 101 (5.8%) | 84 (4.8%) | 68 (3.9%) |
| Age group | |||||||||
| 18–49 y.o. | 496 (28.3%) | 131 (23.3%) | 365 (30.7%) | 23 (35.4%) | 40 (22.7%) | 23 (29.9%) | 19 (18.8%) | 21 (25.0%) | 8 (11.8%) |
| 50–64 y.o. | 442 (25.2%) | 149 (26.5%) | 293 (24.6%) | 28 (43.1%) | 33 (18.8%) | 17 (22.1%) | 25 (24.8%) | 23 (27.4%) | 24 (35.3%) |
| 65 + y.o. | 815 (46.5%) | 283 (50.3%) | 532 (44.7%) | 14 (21.6%)* | 104 (58.8%)^ | 37 (48.1%)^ | 57 (56.4%)^ | 40 (47.6%)^ | 36 (52.9%)^ |
| Female | 845 (48.2%) | 279 (49.6%) | 566 (47.6%) | 26 (40.0%) | 90 (50.8%) | 40 (52.0%) | 58 (57.4%) | 40 (47.6%) | 34 (50.0%) |
| Comorbidities | 878 (50.1%) | 276 (49.0%) | 602 (50.6%) | 29 (44.6%) | 75 (42.4%) | 33 (42.9%) | 61 (60.4%)* | 50 (59.5%)* | 34 (50.0%) |
| COPD | 324 (18.5%) | 96 (17.1%) | 228 (19.1%) | 9 (13.9%) | 24 (13.6%) | 10 (13.0%) | 29 (28.7%)*^ | 11 (13.1%) | 15 (22.1%) |
| CVD | 172 (9.8%) | 63 (11.2%) | 109 (9.2%) | 9 (13.9%) | 17 (9.6%) | 8 (10.4%) | 14 (13.9%) | 9 (10.7%) | 7 (10.3%) |
| Diabetes | 193 (11.0%) | 72 (12.8%) | 121 (10.2%) | 6 (9.2%) | 24 (13.6%) | 9 (11.7%) | 8 (7.9%) | 18 (21.4%) | 7 (10.3%) |
| Immuno compromised | 184 (10.5%) | 50 (8.9%) | 134 (11.3%) | 7 (10.8%) | 11 (6.2%) | 3 (3.9%) | 10 (9.9%) | 14 (16.7%)* | 5 (7.4%) |
| Asthma | 131 (7.5%) | 44 (7.8%) | 87 (7.3%) | 2 (3.1%) | 15 (8.5%) | 3 (3.9%) | 11 (10.9%) | 12 (14.3%)^ | 5 (7.4%) |
| Cystic fibrosis | 30 (1.7%) | 5 (0.9%) | 25 (2.1%) | 1 (1.5%) | 1 (0.6%) | 2 (2.6%) | 0 (0%) | 0 (0%) | 0 (0%) |
*Statistically significant difference compared to A/H3 in univariate analysis. ^Statistically significant difference compared to A/H1 in univariate analysis.